首页> 外文期刊>Bulletin of the Korean Chemical Society >Investigation of the Binding Site of CCR2 using 4-Azetidinyl-1-aryl-cyclohexane Derivatives: A Membrane Modeling and Molecular Dynamics Study
【24h】

Investigation of the Binding Site of CCR2 using 4-Azetidinyl-1-aryl-cyclohexane Derivatives: A Membrane Modeling and Molecular Dynamics Study

机译:使用4-氮杂环丁烷基-1-芳基-环己烷衍生物研究CCR2的结合位点:膜建模和分子动力学研究。

获取原文
           

摘要

Chemokine receptor (CCR2) is a G protein-coupled receptor that contains seven transmembrane helices. Recent pharmaceutical research has focused on the antagonism of CCR2 and candidate drugs are currently undergoing clinical studies for the treatment of diseases like arthritis, multiple sclerosis, and type 2 diabetes. In this study, we analyzed the time dependent behavior of CCR2 docked with a potent 4-azetidinyl-1-arylcyclohexane (4AAC) derivative using molecular dynamics simulations (MDS) for 20 nanoseconds (ns). Homology modeling of CCR2 was performed and the 4AAC derivative was docked into this binding site. The docked model of selected conformations was then utilized to study the dynamic behavior of the 4AAC enzyme complexes inside lipid membrane. MDS of CCR2-16b of 4AAC complexes allowed us to refine the system since binding of an inhibitor to a receptor is a dynamic process and identify stable structures and better binding modes. Structure activity relationships (SAR) for 4AAC derivatives were investigated and reasons for the activities were determined. Probable binding pose for some CCR2 antagonists were determined from the perspectives of binding site. Initial modeling showed that Tyr49, Trp98, Ser101, Glu291, and additional residues are crucial for 4AAC binding, but MDS analysis showed that Ser101 may not be vital. 4AAC moved away from Ser101 and the hydrogen bonding between 4AAC and Ser101 vanished. The results of this study provide useful information regarding the structure-based drug design of CCR2 antagonists and additionally suggest key residues for further study by mutagenesis.
机译:趋化因子受体(CCR2)是一种G蛋白偶联受体,包含七个跨膜螺旋。最近的药物研究集中于CCR2的拮抗作用,目前候选药物正在临床研究中,以治疗关节炎,多发性硬化症和2型糖尿病。在这项研究中,我们使用分子动力学模拟(MDS)分析了20纳秒(ns)与强效4-氮杂环丁烷基-1-芳基环己烷(4AAC)衍生物对接的CCR2的时间依赖性行为。进行CCR2的同源性建模,并将4AAC衍生物对接至该结合位点。然后利用所选构象的对接模型研究脂质膜内部4AAC酶复合物的动力学行为。 4AAC复合物的CCR2-16b的MDS使我们能够完善系统,因为抑制剂与受体的结合是一个动态过程,并且可以确定稳定的结构和更好的结合方式。研究了4AAC衍生物的结构活性关系(SAR),并确定了活性的原因。从结合位点的角度确定了某些CCR2拮抗剂可能的结合姿势。初步建模显示,Tyr49,Trp98,Ser101,Glu291和其他残基对于4AAC结合至关重要,但MDS分析表明,Ser101可能并不重要。 4AAC从Ser101移开,并且4AAC和Ser101之间的氢键消失。这项研究的结果提供了有关CCR2拮抗剂基于结构的药物设计的有用信息,并且还提出了关键的残基,可通过诱变进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号